Dr. Usmani on Ibrutinib/Carfilzomib in Patients With Multiple Myeloma

Saad Z. Usmani, MD
Published: Friday, Dec 04, 2015



Saad Z. Usmani, MD, hematology and medical oncology, Levine Cancer Institute, Carolinas HealthCare System, discusses results of a phase Ib/II study examining the combination of ibrutinib plus carfilzomib in patients with relapsed/refractory multiple myeloma.

Patients who were eligible to receive the combination were pretreated with bortezomib and an immunomodulatory agent, Usmani explains. The median prior lines of therapy was three; 25% of patients had previous exposure to carfilzomib and pomalidomide.

The highest dose of ibrutinib administered to patients was 560 mg, while the highest dose of carfilzomib was 227 mg. In the combination arm, the overall response rate was approximately 58% and the clinical benefit rate was 67%. No significant toxicities were seen with the combination, Usmani adds. Next steps include a dose expansion as well as a phase III study.

<<< View more from the 2015 ASH Annual Meeting



Saad Z. Usmani, MD, hematology and medical oncology, Levine Cancer Institute, Carolinas HealthCare System, discusses results of a phase Ib/II study examining the combination of ibrutinib plus carfilzomib in patients with relapsed/refractory multiple myeloma.

Patients who were eligible to receive the combination were pretreated with bortezomib and an immunomodulatory agent, Usmani explains. The median prior lines of therapy was three; 25% of patients had previous exposure to carfilzomib and pomalidomide.

The highest dose of ibrutinib administered to patients was 560 mg, while the highest dose of carfilzomib was 227 mg. In the combination arm, the overall response rate was approximately 58% and the clinical benefit rate was 67%. No significant toxicities were seen with the combination, Usmani adds. Next steps include a dose expansion as well as a phase III study.

<<< View more from the 2015 ASH Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x